# Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12275288</article-id><article-id pub-id-type="publisher-id">4250</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04250-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA&#x02013;IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ji</surname><given-names>Shuyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sheng</surname><given-names>Zhenxin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bian</surname><given-names>Dongliang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bao</surname><given-names>Minwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jin</surname><given-names>Kaiqi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Wentian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Xinsheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Fenghuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Haoran</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Ziyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Huansha</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lele</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Peng</surname><given-names>Zhang</given-names></name><address><email>zhangpeng1121@tongji.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Song</surname><given-names>Nan</given-names></name><address><email>songnan@tongji.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Haifeng</given-names></name><address><email>nautilus2316@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Qian</surname><given-names>Biyun</given-names></name><address><email>qianbiyun@sjtu.edu.cn</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Yuming</given-names></name><address><email>Ymzhu2005@aliyun.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033nbnf69</institution-id><institution-id institution-id-type="GRID">grid.412532.3</institution-id><institution>Department of Thoracic Surgery, </institution><institution>Shanghai Pulmonary Hospital, Tongji University School of Medicine, </institution></institution-wrap>Shanghai, 200433 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033nbnf69</institution-id><institution-id institution-id-type="GRID">grid.412532.3</institution-id><institution>Experimental Animal Center, </institution><institution>Shanghai Pulmonary Hospital, Tongji University School of Medicine, </institution></institution-wrap>Shanghai, 200433 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033nbnf69</institution-id><institution-id institution-id-type="GRID">grid.412532.3</institution-id><institution>Department of Central Laboratory, School of Medicine, </institution><institution>Shanghai Pulmonary Hospital, Tongji University, </institution></institution-wrap>Shanghai, 200433 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033nbnf69</institution-id><institution-id institution-id-type="GRID">grid.412532.3</institution-id><institution>Department of Clinical Research Center, </institution><institution>Shanghai Pulmonary Hospital, Tongji University School of Medicine, </institution></institution-wrap>Shanghai, 200433 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0220qvk04</institution-id><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution>School of Public Health, </institution><institution>Hongqiao International Institute of Medicine, Shanghai Tong Ren Hospitaland, Shanghai Jiao Tong University School of Medicine
, </institution></institution-wrap>Shanghai, 201103 China </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>429</elocation-id><history><date date-type="received"><day>1</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par12">This study aimed to evaluate the efficacy and safety of camrelizumab, an anti-PD-1 antibody, combined with either chemotherapy or apatinib, a VEGFR-2 inhibitor, as neoadjuvant treatment for stage IIA&#x02013;IIIA NSCLC.</p></sec><sec><title>Methods</title><p id="Par13">This prospective, multicenter, dual-arm, non-randomized phase II trial enrolled participants from four hospitals in China between September 2020 and March 2022. Patients received 2&#x02013;4 cycles of neoadjuvant treatment followed by surgery. Arm-AR (<italic>n</italic>&#x02009;=&#x02009;28) included patients treated with camrelizumab (200&#x000a0;mg every 3&#x000a0;weeks) plus platinum-based chemotherapy, regardless of PD-L1 status. Arm-BR (<italic>n</italic>&#x02009;=&#x02009;10) included PD-L1-positive patients treated with camrelizumab (200&#x000a0;mg every 3&#x000a0;weeks) plus apatinib (250&#x000a0;mg daily). The primary endpoint was the major pathological response (MPR) rate. Secondary endpoints included pathological complete response (pCR) rate, objective response rate (ORR), disease control rate (DCR), event-free survival (EFS), overall survival (OS), and safety profiles.</p></sec><sec><title>Results</title><p id="Par14">In the ITT population, MPR rates were 25.0% (95% CI 10.7&#x02013;44.9) in arm-AR and 60.0% (95% CI 26.2&#x02013;87.8) in arm-BR. The 24-month EFS rates were 53.6% and 70.0%, respectively, after a median follow-up of 30.5&#x000a0;months. Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 25% of arm-AR patients and 10% of arm-BR patients.</p></sec><sec><title>Conclusions</title><p id="Par15">Camrelizumab combined with platinum-based chemotherapy demonstrated promising efficacy and tolerability for resectable IIA&#x02013;IIIA NSCLC, regardless of PD-L1 status. In PD-L1-positive patients, camrelizumab plus apatinib showed improved safety and effectiveness, highlighting a potential treatment option for this subgroup.</p><p id="Par16">Trial registration.</p><p id="Par17">NCT04379739, initiated on July 26, 2020.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04250-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Non-small-cell lung cancer</kwd><kwd>Neoadjuvant</kwd><kwd>Camrelizumab</kwd><kwd>Apatinib</kwd><kwd>Major pathologic response</kwd></kwd-group><funding-group><award-group><funding-source><institution>Shanghai Pulmonary Hospital Fund</institution></funding-source><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id><award-id>FKLY20004 and FKCX2304</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100018904</institution-id><institution>Beijing Xisike Clinical Oncology Research Foundation</institution></institution-wrap></funding-source><award-id>Y-HR2019-0451</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Shanghai Municipal Education Commission</institution></funding-source><award-id>2023ZKZD33</award-id><award-id>2023ZKZD33</award-id><award-id>2023ZKZD33</award-id><award-id>2023ZKZD33</award-id><award-id>2023ZKZD33</award-id><award-id>2023ZKZD33</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82125001</award-id><award-id>82125001</award-id><award-id>82125001</award-id><award-id>82125001</award-id><award-id>82125001</award-id><award-id>82125001</award-id><award-id>82125001</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec2"><title>Background</title><p id="Par42">Lung cancer is the most prevalent malignant tumor worldwide, with approximately 2.48 million new cases and 1.81 million deaths in 2022 [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>].&#x000a0;Of these, non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases, with adenocarcinoma, squamous cell carcinoma, and large cell carcinoma being the predominant subtypes. For NSCLC in early stage, surgery remains the most effective treatment; however, 30% to 77% of patients in stage II&#x02013;III experience recurrence postoperatively [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. For resectable NSCLC, the results of several randomized phase III trials (CheckMate 816, KEYNOTE-671, and Neotorch) demonstrate the feasibility of neoadjuvant immunochemotherapy [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], which could significantly improve the efficacy compared to neoadjuvant chemotherapy. Thus, several immunotherapy agents have been approved for the perioperative treatment of resectable NSCLC.
</p><p id="Par43">Nevertheless, previous trials demonstrated that, for PD-L1 (an immune checkpoint protein mediating immune escape) highly expressed advanced NSCLC, patients receiving PD-1 mono-immunotherapy probably had similar therapeutic efficacy to those who received chemo-immunotherapy[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, the neoadjuvant chemotherapy-free regimens have also gained sustained attention in the fields of thoracic surgery and oncology. The published results in this trial demonstrated the efficacy and safety of neoadjuvant camrelizumab, a humanized high-affinity IgG4-kappa anti-PD-1 monoclonal antibody, combined with chemotherapy or apatinib, a tyrosine kinase inhibitor targeting VEGFR-2, for the initially unresectable cohort [<xref ref-type="bibr" rid="CR3">3</xref>]. Our phase II umbrella clinical trial in unresectable stage III NSCLC also confirmed this finding [<xref ref-type="bibr" rid="CR11">11</xref>]. These findings were further corroborated by the EAST ENERGY trial (NCT04040361), in which the combination of pembrolizumab (PD-1 inhibitor)) and ramucirumab (VEGFR-2 inhibitor) achieved a 66.7% MPR rate in PD-L1-positive resectable NSCLC [<xref ref-type="bibr" rid="CR12">12</xref>]. Mechanistically, the synergy between PD-1 and VEGFR-2 inhibitors stems from VEGF/VEGFR-2 blockade&#x02013;induced vascular normalization, which enhances T cell infiltration, augments dendritic cell activation, and suppresses regulatory T cell mediated immunosuppression [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par44">To further explore the potential of neoadjuvant immunotherapy combination regimens, this multicenter, phase II trial evaluates the efficacy and safety of camrelizumab in combination with either platinum-based chemotherapy (arm-AR) or apatinib (arm-BR) as neoadjuvant treatments for patients with resectable stage IIA&#x02013;IIIA NSCLC [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Study design</title><p id="Par45">This study is a prospective, multicenter, dual-arm, non-randomized, phase II exploratory trial conducted in China (NCT04379739). The inclusion criteria for patients were: aged between 18 and 75&#x000a0;years old; histologically or cytologically confirmed, untreated stage II-III NSCLC (based on the eighth edition of the American Joint Committee on Cancer TNM staging system for lung cancer); an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1; measurable lesions according to RECIST criteria version 1.1; and adequate functional reserve of key organs. arm-AR included all patients with any level of PD-L1 expression. arm-BR included patients exhibiting a baseline PD-L1 expression of 1% or greater, provided that they had no uncontrolled hypertension, no history of thrombotic events, and no significant bleeding tendencies. Key exclusion criteria for both arms included: known mutations in <italic>EGFR</italic> or <italic>ALK</italic>; a history of autoimmune diseases; a history of other malignancies within the past 5&#x000a0;years; or prior receipt of systemic corticosteroid therapy (&#x0003e;&#x02009;10&#x000a0;mg/day prednisone equivalent) or other immunosuppressive agents within 2&#x000a0;weeks preceding study initiation. Patients with tumors deemed initially unresectable were also excluded, based on assessments from a multidisciplinary clinical team (MDT). These unresectable cases were characterized by (1) tumor invading vital structures, such as large blood vessels, the trachea or primary bronchus, but curative resection after tumor downgrading by neoadjuvant therapy was possible as judged by a preoperative assessment; (2) clinically confirmed lymph nodes with multistation metastasis or bulky fusion, and patients could tolerate hilar and mediastinal lymph node dissection after tumor downgrading by neoadjuvant therapy as determined by a preoperative evaluation; or (3) according to preoperative evaluation, even if pneumonectomy was performed, especially right pneumonectomy, R0 resection may not be achieved.</p></sec><sec id="Sec5"><title>Procedures</title><p id="Par46">All participants received predefined neoadjuvant therapy and were included in the ITT population. Both arm-AR and arm-BR underwent 2 to 4 cycles of camrelizumab-based treatment (200&#x000a0;mg/3&#x000a0;weeks): arm-AR combined with chemotherapy, and arm-BR with apatinib (250&#x000a0;mg daily). For those diagnosed with squamous NSCLC, the chemotherapy regimen comprised carboplatin (AUC 5 on day 1) alongside gemcitabine (1000&#x000a0;mg/m<sup>2</sup> on days 1 and 8), or alternatively paclitaxel (135&#x02013;175&#x000a0;mg/m<sup>2</sup>), or nab-paclitaxel (260&#x000a0;mg/m<sup>2</sup>), all administered on day 1. In contrast, patients with non-squamous NSCLC were treated with carboplatin (AUC 5 on day 1) in combination with pemetrexed (500&#x000a0;mg/m<sup>2</sup> on day 1).</p><p id="Par47">For the assessment of surgical candidacy, patients who have completed two to four treatment cycles underwent a contrast-enhanced computed tomography (CT) scan of the chest. In cases where the tumor met the criteria for complete response (CR), partial response (PR) or stable disease (SD) as defined by RECIST version 1.1, the MDT conducted a further evaluation to determine surgical suitability. Assessment criteria include tumor location, extent of tumor invasion, lymph node status, and the patient&#x02019;s overall systemic condition. Surgery for eligible patients was anticipated to occur within 30&#x000a0;days following tumor evaluation. The pathological response will be evaluated as previously described. Postoperatively, patients underwent a chest CT scan 30&#x000a0;days after surgery, followed by CT examinations every 3&#x000a0;months during the first 2&#x000a0;years and every 6&#x000a0;months from the third to fifth years.</p><p id="Par48">Throughout the entire trial period, AEs were rigorously monitored and systematically graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Furthermore, the baseline PD-L1 tumor proportion score was quantitatively assessed using the 22C3 pharmDx assay (Agilent Technologies, CA, USA). Decisions regarding postoperative adjuvant therapy were individually tailored by a multidisciplinary team based on comprehensive postoperative pathological characteristics (including ypTNM stage and tumor regression grade), ECOG performance status, and organ functional reserve.</p></sec><sec id="Sec6"><title>Endpoints</title><p id="Par49">The primary endpoint was the MPR rate, defined as the percentage of patients with&#x02009;&#x02264;&#x02009;10% viable tumor cells after resection. The evaluation of MPR was conducted post-resection, following the completion of neoadjuvant therapy, through pathological analysis of the resected tumor tissue. Secondary endpoints included the pCR rate (no viable tumor cells post-resection) and ORR (patients achieving CR or PR per RECIST 1.1). EFS was tracked from the start of neoadjuvant therapy to disease progression, recurrence, or death. Additionally, OS (time from therapy initiation to death), R0 resection rate (negative margins), and safety profiles were assessed.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par50">Sample size calculations using R&#x02019;s clinfun package determined: (1) Arm-AR (<italic>n</italic>&#x02009;=&#x02009;28) required to detect MPR improvement from 8.9% (historical control) to 30%; (2) Arm-BR (<italic>n</italic>&#x02009;=&#x02009;10) to distinguish 8.9% vs 45% MPR rates, both with one-sided <italic>&#x003b1;</italic>&#x02009;=&#x02009;0.05 and 80% power [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The response-related endpoints were assessed in the efficacy analysis population, which encompassed all patients who had received at least one dose of neoadjuvant therapy and subsequently underwent surgery. In contrast, analyses pertaining to survival and safety were conducted within the full analysis population, comprising all patients who had received at least one dose of neoadjuvant therapy. The 95% CIs for metrics such as MPR rate, pCR rate, ORR, and R0 resection rate were derived using the binom package, following the Clopper-Pearson method. Survival curves were fitted using the survival package, employing the Kaplan&#x02013;Meier method, and 95% CIs were calculated using the log&#x02013;log method to ensure robust estimates, particularly at the tails of the survival curves. TRAEs were reported as frequencies (percentages). Additionally, post hoc analyses investigated EFS and OS by stratifying patients based on whether they had undergone surgery. All statistical analyses were conducted using R version 4.2.3.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Patients</title><p id="Par51">Between September 11, 2020, and March 14, 2022, the MA-NSCLC-II-001 Study enrolled 89 participants: 51 initially unresectable and 38 resectable patients. The findings for the initially unresectable cohort have already been published[<xref ref-type="bibr" rid="CR3">3</xref>]. Among the resectable patients, arm-AR and arm-BR enrolled 28 and 10 participants, respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Baseline characteristics for both groups were detailed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. In arm-AR, the median diagnostic age was 65 (range, 62.8&#x02013;69.0). The majority of participants in arm-AR were male (92.9%, 26/28), diagnosed with squamous cell carcinoma (LUSQ) (67.9%, 19/28), had an ECOG PS score of 0 (78.6%, 22/28), were categorized as clinical stage IIIA (64.3%, 18/28), and had PD-L1 expression&#x02009;&#x0003c;&#x02009;1% or unknown (60.7%, 17/28). In arm-BR, the median diagnostic age was 67.5 (range, 66.0&#x02013;69.8). Male&#x000a0;(90%, 9/10), LUSQ (80%, 8/10), ECOG PS of 1 (60%, 6/10), and stage IIIA (70%, 7/10) participants accounted for the majority.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The clinical trial design. This phase II trial evaluated neoadjuvant camrelizumab (anti-PD-1) combined with chemotherapy (arms AR/AuR) or apatinib (VEGFR-2 inhibitor; arms BR/BuR) in resectable (<italic>n</italic>&#x02009;=&#x02009;38) and initially unresectable (<italic>n</italic>&#x02009;=&#x02009;51) NSCLC. Arm-AR,</p></caption><graphic xlink:href="12916_2025_4250_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of patients with resectable NSCLC in arm-AR and arm-BR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Arm-AR (<italic>n</italic>&#x02009;=&#x02009;28)</th><th align="left">Arm-BR (<italic>n</italic>&#x02009;=&#x02009;10)</th></tr></thead><tbody><tr><td align="left">Age (median [IQR])</td><td align="left">65.00 [62.8, 69.0]</td><td align="left">67.50 [66.0, 69.8]</td></tr><tr><td align="left">Sex (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Male</td><td align="left">26 (92.9)</td><td align="left">9 (90.0)</td></tr><tr><td align="left">Female</td><td align="left">2 (7.1)</td><td align="left">1 (10.0)</td></tr><tr><td align="left">ECOG performance status, <bold><italic>n</italic></bold> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td align="left">22 (78.6)</td><td align="left">4 (40.0)</td></tr><tr><td align="left">1</td><td align="left">6 (21.4)</td><td align="left">6 (60.0)</td></tr><tr><td align="left">Smoking, <bold><italic>n</italic></bold> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Former/current smoker</td><td align="left">20 (71.4)</td><td align="left">9 (90.0)</td></tr><tr><td align="left">Non-smoker</td><td align="left">8 (28.6)</td><td align="left">1 (10.0)</td></tr><tr><td align="left">Clinical stage (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">IIA</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">IIB</td><td align="left">9 (32.1)</td><td align="left">3 (30.0)</td></tr><tr><td align="left">IIIA</td><td align="left">18 (64.3)</td><td align="left">7 (70.0)</td></tr><tr><td align="left">Clinical nodal status, <bold><italic>n</italic></bold> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">N0</td><td align="left">8 (28.6)</td><td align="left">2 (20.0)</td></tr><tr><td align="left">N1</td><td align="left">12 (42.9)</td><td align="left">4 (40.0)</td></tr><tr><td align="left">N2</td><td align="left">8 (28.6)</td><td align="left">4 (40.0)</td></tr><tr><td align="left">Histological type, <bold><italic>n</italic></bold> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Squamous cell carcinoma</td><td align="left">19 (67.9)</td><td align="left">8 (80.0)</td></tr><tr><td align="left">Non-squamous cell carcinoma</td><td align="left">9 (32.1)</td><td align="left">2 (20.0)</td></tr><tr><td align="left">PD-L1 expression, <bold><italic>n</italic></bold> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02009;&#x0003c;&#x02009;1%</td><td align="left">6 (21.4)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">1&#x02013;49%</td><td align="left">5 (17.9)</td><td align="left">7 (70.0)</td></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;50%</td><td align="left">6 (21.4)</td><td align="left">3 (30.0)</td></tr><tr><td align="left">Unknown</td><td align="left">11 (39.3)</td><td align="left">0 (0.0)</td></tr></tbody></table><table-wrap-foot><p><italic>&#x000a0;IQR</italic> Interquartile Range; <italic>ECOG</italic> Eastern Cooperative Oncology Group; <italic>PD-L1</italic>&#x000a0;Programmed Death Ligand 1.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Efficacy</title><p id="Par52">In the ITT patients of arm-AR, 25% (7/28, 95% CI 10.7&#x02013;44.9) of patients achieved MPR, 17.9% (5/28, 95% CI 6.1&#x02013;36.9) achieved pCR, and 67.9% had an ORR, while 85.7% had DCR. The proportion of CR, PR, and SD was 7.1%, 60.7%, and 17.9%, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In arm-BR, the MPR and pCR rates were 60.0% and 10.0%, respectively. The ORR and DCR were 70.0% and 90.0%, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Pathological downstaging rates reached 77.3% (17/22) in arm-AR and 88.9% (8/9) in arm-BR (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). The low response rates were linked to the predominance of stage IIIA in both arms and low PD-L1 expression in most arm-AR patients. Furthermore, 6 patients and 1 patient did not undergo surgery in arm-AR and arm-BR, respectively. Among patients undergoing surgery, the MPR, pCR, and ORR for arm-AR were 31.8% (7/22, 95% CI 13.9&#x02013;54.9), 22.7% (5/22, 95% CI 7.8&#x02013;45.4), and 81.8% (18/22, 95% CI 59.7&#x02013;94.8), respectively. In arm-BR, these rates were 66.7% (6/9, 95% CI 29.9&#x02013;92.5), 11.1% (1/9, 95% CI 0.3&#x02013;48.2), and 77.8% (7/9, 95% CI 40&#x02013;97.2), respectively (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1 and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S1). A correlative analysis was conducted between MPR and clinicopathologic variables within surgical cohorts. In arm-AR (<italic>n</italic>&#x02009;=&#x02009;22), numerical trends indicated a higher prevalence of PD-L1 expression&#x02009;&#x02265;&#x02009;50% (42.9% vs. 20.0%, <italic>p</italic>&#x02009;=&#x02009;0.350) and squamous cell carcinoma predominance (85.7% vs. 60.0%, <italic>p</italic>&#x02009;=&#x02009;0.350) in the MPR group (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2). In arm-BR (<italic>n</italic>&#x02009;=&#x02009;9), the MPR group exhibited a greater frequency of N2 nodal involvement (50.0% vs. 0%, <italic>p</italic>&#x02009;=&#x02009;0.143) and stage IIIA disease (83.3% vs. 33.3%, <italic>p</italic>&#x02009;=&#x02009;0.226) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Response rates in intention-to-treat patients treated with neoadjuvant camrelizumab-based regimens</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Efficacy outcomes</th><th align="left">Arm-AR (<italic>n</italic>&#x02009;=&#x02009;28)</th><th align="left">Arm-BR (<italic>n</italic>&#x02009;=&#x02009;10)</th></tr></thead><tbody><tr><td align="left">Pathological response, <bold><italic>n</italic></bold> (%, 95% CI)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Major pathological response</td><td align="left">7 (25.0, 10.7&#x02013;44.9)</td><td align="left">6 (60.0, 26.2&#x02013;87.8)</td></tr><tr><td align="left">Pathological complete response</td><td align="left">5 (17.9, 6.1&#x02013;36.9)</td><td align="left">1 (10.0, 0.3&#x02013;44.5)</td></tr><tr><td align="left">Best overall response, <bold><italic>n</italic></bold> (%)</td><td align="left"/><td align="left"/></tr><tr><td align="left">Complete response</td><td align="left">2 (7.1)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Partial response</td><td align="left">17 (60.7)</td><td align="left">7 (70.0)</td></tr><tr><td align="left">Stable disease</td><td align="left">5 (17.9)</td><td align="left">2 (20.0)</td></tr><tr><td align="left">Progressive disease</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Not evaluable</td><td align="left">3 (10.7)</td><td align="left">1 (10.0)</td></tr><tr><td align="left">Objective response rate, % (95% CI)</td><td align="left">67.9 (47.6&#x02013;84.1)</td><td align="left">70.0 (34.8&#x02013;93.3)</td></tr></tbody></table><table-wrap-foot><p><italic>&#x000a0;CI </italic>Confidence Interval</p></table-wrap-foot></table-wrap></p><p id="Par53">By November 8, 2024, with a median follow-up of 30.5&#x000a0;months, the median EFS of arm-AR and arm-BR was 24.8&#x000a0;months (95% CI 12.1&#x02013;NR) and 28.7&#x000a0;months (95% CI 2.4&#x02013;NR). The 12-month/24-month EFS of arm-AR and arm-BR was 71.4%/53.6% and 70.0%/70.0% (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a&#x02013;b). Patients achieving pathological downstaging showed higher 24-month EFS (67.4% vs 33.3%, <italic>p</italic>&#x02009;=&#x02009;0.068) (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S2). Additionally, there were 15 deaths in arm-AR and 3 in arm-BR. The median OS of arm-AR and arm-BR was 38.3&#x000a0;months (95% CI 21.7&#x02013;NR) and NR. The 12-month/24-month OS of arm-AR and arm-BR was 89.3%/67.9% and 80.0%/70.0% (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c&#x02013;d).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>EFS and OS outcomes in resectable NSCLC patients treated with neoadjuvant camrelizumab-based regimens. Kaplan&#x02013;Meier curves illustrate EFS (top panels) and OS (bottom panels) for patients receiving camrelizumab combined with chemotherapy (arm-AR, panels <bold>a</bold> and <bold>c</bold>) or apatinib (arm-BR, panels <bold>b</bold> and <bold>d</bold>). EFS, Event-free survival; OS, overall survival</p></caption><graphic xlink:href="12916_2025_4250_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec11"><title>Safety</title><p id="Par54">In arm-AR, TRAEs were observed in 78.6% (22/28) participants. Grade 3/4 TRAEs occurred in 6 participants with cases of neutropenia (10.7%), anemia (7.1%), and renal insufficiency (7.1%). One patient experienced a grade 5 TRAE with bone marrow suppression and immune myocarditis (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Additionally, 8 participants experienced immune-related adverse events (irAEs). The most common cases were reactive cutaneous capillary endothelial proliferation (10.7%, 3/28) and elevated gamma-glutamyl transferase (10.7%, 3/28) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). In arm-BR, all patients experienced TRAEs, with only one (10%) participant experiencing grade 3 hypertension. No grade 4 or 5 events were observed (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Additionally, irAEs were observed in 2 (20%) participants&#x000a0;(Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4). </p><p id="Par55">There were 3 (10.7%) participants in arm-AR who did not complete the pre-specified treatment, due to adverse events such as hyponatremia, hemoptysis, and immune myocarditis. Conversely, only one patient in arm-BR withdrew the informed consent and did not complete the pre-specified treatment.</p><p id="Par56">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Treatment-related adverse events (TRAEs) in patients receiving neoadjuvant camrelizumab-based regimens</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Events,<italic>n</italic>(%)<sup>*</sup></th><th align="left" colspan="2">Arm-AR (<italic>n</italic>&#x02009;=&#x02009;28)</th><th align="left" colspan="2">Arm-BR (<italic>n</italic>&#x02009;=&#x02009;10)</th></tr><tr><th align="left"><bold>Any grade</bold></th><th align="left"><bold>Grade&#x02009;&#x02265;&#x02009;3</bold></th><th align="left"><bold>Any grade</bold></th><th align="left"><bold>Grade&#x02009;&#x02265;&#x02009;3</bold></th></tr></thead><tbody><tr><td align="left">Any</td><td align="left">22 (78.6)</td><td align="left">7 (25.0)</td><td align="left">10 (100.0)</td><td align="left">1 (10.0)</td></tr><tr><td align="left">Anemia</td><td align="left">9 (32.1)</td><td align="left">2 (7.1)</td><td align="left">1 (10.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Neutrophil count decreased</td><td align="left">7 (25.0)</td><td align="left">3 (10.7)</td><td align="left">1 (10.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">White blood cell count decreased</td><td align="left">7 (25.0)</td><td align="left">1 (3.6)</td><td align="left">1 (10.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Gamma glutamyl transferase increased</td><td align="left">6 (21.4)</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Platelet count decreased</td><td align="left">4 (14.3)</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Alanine aminotransferase increased</td><td align="left">3 (10.7)</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Reactive capillary endothelial hyperplasia</td><td align="left">3 (10.7)</td><td align="left">0 (0.0)</td><td align="left">1 (10.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Blood glucose increased</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Alkaline phosphatase increased</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td><td align="left">1 (10.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Aspartate aminotransferase increased</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Proteinuria</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td><td align="left">2 (20.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Renal insufficiency</td><td align="left">2 (7.1)</td><td align="left">2 (7.1)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Hypohepatia</td><td align="left">1 (3.6)</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Bone marrow suppression</td><td align="left">1 (3.6)</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Autoimmune myocarditis</td><td align="left">1 (3.6)</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Hyponatremia</td><td align="left">1 (3.6)</td><td align="left">1 (3.6)</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td></tr><tr><td align="left">Hypertension</td><td align="left">0 (0.0)</td><td align="left">0 (0.0)</td><td align="left">1 (10.0)</td><td align="left">1 (10.0)</td></tr></tbody></table><table-wrap-foot><p>*Data presented for treatment-related adverse events (TRAEs) occurring in at least 5% of patients, or any TRAEs of grade 3 or above in either arm</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Surgery</title><p id="Par57">In arm-AR, the surgical rate and R0 resection rate were 78.6% (22/28) and 95.5% (21/22), respectively, while in arm-BR, these rates were 90% (9/10) and 100% (9/9) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S5). Video-assisted thoracoscopic surgery (VATS) was the most common approach in both arms, with 72.7% (16/22) in arm-AR and 66.7% (6/9) in arm-BR. Lobectomy was the most frequent procedure, accounting for 72.7% (16/22) in arm-AR and 55.6% (5/9) in arm-BR (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S5 and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Fig. S3). Among the six non-surgically treated patients in arm-AR, two withdrew informed consent, two experienced grade&#x02009;&#x02265;&#x02009;3 TRAEs (immune myocarditis and chemotherapy-induced nephrotoxicity), one had disease progression, and one died from tumor-related hemoptysis. In arm-BR, only one patient did not receive surgery after withdrawing the informed consent.</p><p id="Par58">Furthermore, two surgically treated patients (9.1%) in arm-AR experienced postoperative complications, including pulmonary embolism and bleeding. No postoperative complications occurred in arm-BR, and no deaths were reported within 90&#x000a0;days after surgery in either arm.</p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par59">This multicenter, two-arm, phase II trial met its primary endpoint, with 25.0% (7/28) of patients in arm-AR and 60% (6/10) in arm-BR achieving MPR. The pCR rates were 17.9% (5/28) for arm-AR and 10% (1/10) for arm-BR. Compared to historical controls from neoadjuvant chemotherapy (CheckMate 816&#x02019;s chemotherapy arm: MPR 8.9%, pCR 2.2%) [<xref ref-type="bibr" rid="CR6">6</xref>] and neoadjuvant immunotherapy monotherapy (LCMC3: MPR 20.0%, pCR 6.0%) [<xref ref-type="bibr" rid="CR17">17</xref>], the arm-AR regimen appeared to show improved efficacy in unselected PD-L1 populations. Additionally, the pCR rate of the arm-AR regimen (17.9%) approached that of the KEYNOTE-671&#x02019;s pembrolizumab-chemotherapy combination (18.0%) [<xref ref-type="bibr" rid="CR18">18</xref>]. In PD-L1-positive subgroups, arm-BR achieved a 60.0% MPR rate, tripling LCMC3&#x02019;s immunotherapy-alone results and doubling KEYNOTE-671&#x02019;s chemo-immunotherapy outcomes. This aligns with Jun Zhao&#x02019;s camrelizumab-apatinib study (MPR 47% [<xref ref-type="bibr" rid="CR19">19</xref>]).</p><p id="Par60">Across both arms, most camrelizumab-related AEs were mild (Grade 1/2), predominantly reactive cutaneous capillary endothelial proliferation, echoing results from camrelizumab-based therapies [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. The safety profiles of both regimens support their clinical utility. Arm-AR showed a lower incidence of grade&#x02009;&#x02265;&#x02009;3 TRAEs at 25.0%, compared with 33.5% in the nivolumab-chemotherapy arm of CheckMate 816 [<xref ref-type="bibr" rid="CR6">6</xref>]. Additionally, immune-related adverse events were more manageable in arm-AR (28.6% vs. 41% in the atezolizumab monotherapy arm of LCMC3 [<xref ref-type="bibr" rid="CR17">17</xref>]). Arm-BR exhibited minimal severe toxicities, with only 10% of patients experiencing grade&#x02009;&#x02265;&#x02009;3 TRAEs and no grade&#x02009;&#x02265;&#x02009;4 irAEs, outperforming other chemotherapy-free regimens such as SHR-1701 (PD-L1/TGF-&#x003b2; bifunctional antibody) monotherapy, which reported 40% grade&#x02009;&#x02265;&#x02009;3 TRAEs [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par61">In preceding research,&#x000a0;we also investigated the efficacy and safety profile of neoadjuvant camrelizumab in combination with chemotherapy and apatinib in patients initially unresectable [<xref ref-type="bibr" rid="CR3">3</xref>]. The MPR and pCR rates for arm-AuR (unresectable arm A) were both 10.0% (3/30). In contrast, arm-BuR (unresectable arm B) showed an MPR rate of 23.8% (5/21) and a pCR rate of 4.8% (1/21). These results suggest that both treatment regimens offer promising efficacy with a manageable safety profile [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Building on the predominant use of neoadjuvant immunotherapy for resectable tumors, we broadened the study to encompass patients with initially operable disease. Within this same framework, a total of 58 patients were enrolled in arm-A (mixed resectable/unresectable arm-A) and 31 in arm-B (mixed resectable/unresectable arm-B). The MPR rates were 17.2% (10/58) for arm-A and 35.5% (11/31) for arm-B, while pCR rates were 13.8% (8/58) and 6.5% (2/31). The ORR was 46.6% (27/58) in arm-A and 45.2% (14/31) in arm-B, with surgery rates of 63.8% (37/58) in arm-A and 58.1% (18/31) in arm-B. This study extends our previous findings in patients with unresectable NSCLC by assessing the safety and efficacy of camrelizumab in combination with chemotherapy or apatinib in patients with resectable stage IIA&#x02013;IIIA disease.</p><p id="Par62">Furthermore, a prospective single-arm, single-center study investigating neoadjuvant camrelizumab combined with apatinib produced results analogous to those of arm-BR in our study, reporting MPR and pCR rates of 57% and 23%, respectively [<xref ref-type="bibr" rid="CR27">27</xref>]. Notably, our arm-BR cohort demonstrated overlapping efficacy ranges with Jun Zhao et al.&#x02019;s study in MPR (60.0% vs 47%, 95% CI overlap) and pCR (10.0% vs 19.2%, CI overlap), while exhibiting a higher surgical conversion rate (90% vs 83%) and consistent biomarker correlations (PD-L1-high subgroup MPR: 100% vs 90%). These findings collectively suggest that both neoadjuvant chemoimmunotherapy and neoadjuvant immunotherapy combined with anti-angiogenic therapy offer viable and effective treatment options for patients with resectable NSCLC. Particularly, the latter, as a chemotherapy-free regimen, holds promise as a valuable alternative for patients who are either unable to tolerate chemotherapy or are apprehensive about its adverse effects.</p><p id="Par63">The predictive role of PD-L1 expression levels in the efficacy of ICIs combined with anti-angiogenic agents remains debated. While PD-L1 status lacks predictive value in advanced solid tumors [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], some evidence in neoadjuvant settings suggests a correlation between higher PD-L1 levels and MPR [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. This supports selecting patients with PD-L1 expression&#x02009;&#x02265;&#x02009;1% for arm-BR. Specifically, the HARMONi-5 study and findings by Zhaojun et al. demonstrated that NSCLC patients with PD-L1&#x02009;&#x02265;&#x02009;1% achieved significantly higher major pathological and objective response rates with immunotherapy&#x02013;antiangiogenic therapy than those with lower PD-L1 levels [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par64">This study has several limitations. Primarily, due to its exploratory design, the sample size was relatively small, particularly the limited sample size in arm-BR, which may constrain the generalizability of conclusions derived from this group. The lack of a randomization or a control group, which limits the ability to make definitive claims about the superiority of one regimen over another, is also a concern. Although no statistically significant differences in MPR rates were observed between chemotherapy groups, the heterogeneity inherent in the AR chemotherapy regimen remains a critical consideration. Additionally, imbalances in baseline characteristics between the two arms may introduce selection bias.</p></sec><sec id="Sec14"><title>Conclusions</title><p id="Par65">In synthesis, for patients diagnosed with resectable stage IIA&#x02013;IIIA NSCLC, regardless of PD-L1 expression, the neoadjuvant administration of camrelizumab in combination with platinum-based doublet chemotherapy has preliminarily shown promising efficacy and manageable toxicity. Furthermore, the treatment strategy of camrelizumab combined with apatinib has also been demonstrated to be effective and safe for PD-L1-positive patients with stage IIA&#x02013;IIIA NSCLC.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4250_MOESM1_ESM.pdf"><caption><p>Additional file 1.&#x000a0;Table S1: Response rates in surgical patients. Table S2: Links to MPR in arms AR. Table S3: Links to MPR in arms BR. Table S4: Immune-related adverse events. Table S5: Surgical outcomes</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4250_MOESM2_ESM.docx"><caption><p>Additional file 2.&#x000a0;Fig. S1: Pathological response in surgical patients. Fig. S2: Survival comparison based on pathological downstaging. Fig. S3: Comparison of predicted vs. actual surgery</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4250_MOESM3_ESM.pdf"><caption><p>Additional file 3. Clinical protocol</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4250_MOESM4_ESM.doc"><caption><p>Additional file 4.&#x000a0;CONSORT checklist</p></caption></media></supplementary-material></p></sec></body><back><glossary id="AGS1"><title>Abbreviations</title><def-list><def-item><term>NSCLC</term><def><p id="Par18">Non-small cell lung cancer</p></def></def-item><def-item><term>LUSQ</term><def><p id="Par19">Squamous cell carcinoma</p></def></def-item><def-item><term>PD-1</term><def><p id="Par20">Programmed death protein 1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par21">Programmed death ligand 1</p></def></def-item><def-item><term>VEGFR-2</term><def><p id="Par22">Vascular endothelial growth factor receptor 2</p></def></def-item><def-item><term>MPR</term><def><p id="Par23">Major pathological response</p></def></def-item><def-item><term>pCR</term><def><p id="Par24">Pathological complete response</p></def></def-item><def-item><term>ORR</term><def><p id="Par25">Objective response rate</p></def></def-item><def-item><term>DCR</term><def><p id="Par26">Disease control rate</p></def></def-item><def-item><term>EFS</term><def><p id="Par27">Event-free survival</p></def></def-item><def-item><term>OS</term><def><p id="Par28">Overall survival</p></def></def-item><def-item><term>CR</term><def><p id="Par29">Complete response</p></def></def-item><def-item><term>PR</term><def><p id="Par30">Partial response</p></def></def-item><def-item><term>SD</term><def><p id="Par31">Stable disease</p></def></def-item><def-item><term>TRAEs</term><def><p id="Par32">Treatment-related adverse events</p></def></def-item><def-item><term>irAEs</term><def><p id="Par33">Immune-related adverse events</p></def></def-item><def-item><term>ECOG PS</term><def><p id="Par34">Eastern Cooperative Oncology Group Performance Status</p></def></def-item><def-item><term>MDT</term><def><p id="Par35">Multidisciplinary clinical team</p></def></def-item><def-item><term>CT</term><def><p id="Par36">Computed tomography</p></def></def-item><def-item><term>AUC</term><def><p id="Par37">Area under the curve</p></def></def-item><def-item><term>CI</term><def><p id="Par38">Confidence interval</p></def></def-item><def-item><term>IQR</term><def><p id="Par39">Interquartile range</p></def></def-item><def-item><term>RECIST</term><def><p id="Par40">Response Evaluation Criteria In Solid Tumors</p></def></def-item><def-item><term>VATS</term><def><p id="Par41">Video-assisted thoracoscopic surgery</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Shuyu Ji, Zhenxin Sheng, Dongliang Bian, Minwei Bao, Kaiqi Jin, and Wentian Zhang contributed equally as co-first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We extend our sincere appreciation to all participants, whose invaluable contributions were instrumental in ensuring the successful completion of this research.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>P.Z., Y.Z., H.W., N.S. and B.Q. conceived and designed the study. S.J., Z.S1. (Zhenxin Sheng), D.B. and M.B. provided the materials and patients support. M.B., W.Z. and K.J. provided the administrative support. Z.S1., D.B., X.Z., F.S., H.X., H.Z., Z.S2. (Ziyun Shen), H.Y., L.Z. and J.H. collected the data. S.J., Z.S1., D.B., and Z.S2. analyzed and interpreted the data. S.J., Z.S1. and D.B. wrote the draft of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by the National Natural Science Foundation of China (No. 82430053, 82125001), the Innovation Program of the Shanghai Municipal Education Commission (No. 2023ZKZD33), the Shanghai Pulmonary Hospital Fund (No. SKPY2021002, LYRC202402 and FKLY20004), and the Beijing Xisike Clinical Oncology Research Foundation (No. Y-HR2019-0451,&#x000a0;Y-BMS2019-089), alongside support from Jiangsu Hengrui Pharmaceuticals Co., Ltd.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The protocol of this trial is available in the Supplementary Information as Additional file 3. The datasets generated during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate.</title><p id="Par66">The trial was rigorously designed in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines, receiving ethical approval from the institutional review boards of all participating centers (No: 19217XW-1). Prior to enrollment, all patients provided written informed consent.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par67">Not applicable. This manuscript does not contain any individual person&#x02019;s data in any form.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests
</title><p id="Par68">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>263</lpage><?supplied-pmid 38572751?><pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#x02013;63.<pub-id pub-id-type="pmid">38572751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group><article-title>Cancer incidence and mortality in China, 2022</article-title><source>J Natl Cancer Cent</source><year>2024</year><volume>4</volume><issue>1</issue><fpage>47</fpage><lpage>53</lpage><?supplied-pmid 39036382?><pub-id pub-id-type="pmid">39036382</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47&#x02013;53.<pub-id pub-id-type="pmid">39036382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Ruan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bian</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>145</fpage><?supplied-pmid 38871690?><pub-id pub-id-type="pmid">38871690</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Xia H, Zhang H, Ruan Z, Zhang H, Sun L, Chen H, Zhou Y, Zhang L, Bian D, Zhu X, et al. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study. Signal Transduct Target Ther. 2024;9(1):145.<pub-id pub-id-type="pmid">38871690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Aigner C, Batirel H, Huber RM, Jones DR, Sihoe ADL, &#x00160;tupnik T, Brunelli A: Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective. <italic>Eur Respir Rev</italic> 2024, 33(171).</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Lang-Lazdunski</surname><given-names>L</given-names></name></person-group><article-title>Surgery for nonsmall cell lung cancer</article-title><source>Eur Respir Rev</source><year>2013</year><volume>22</volume><issue>129</issue><fpage>382</fpage><lpage>404</lpage><?supplied-pmid 23997065?><pub-id pub-id-type="pmid">23997065</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev. 2013;22(129):382&#x02013;404.<pub-id pub-id-type="pmid">23997065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Forde</surname><given-names>PM</given-names></name><name><surname>Spicer</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Provencio</surname><given-names>M</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Broderick</surname><given-names>SR</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Swanson</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer</article-title><source>N Engl J Med</source><year>2022</year><volume>386</volume><issue>21</issue><fpage>1973</fpage><lpage>1985</lpage><?supplied-pmid 35403841?><pub-id pub-id-type="pmid">35403841</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973&#x02013;85.<pub-id pub-id-type="pmid">35403841</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Wakelee</surname><given-names>H</given-names></name><name><surname>Liberman</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Tsuboi</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>KN</given-names></name><name><surname>Dooms</surname><given-names>C</given-names></name><name><surname>Majem</surname><given-names>M</given-names></name><name><surname>Eigendorff</surname><given-names>E</given-names></name><etal/></person-group><article-title>Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>6</issue><fpage>491</fpage><lpage>503</lpage><?supplied-pmid 37272513?><pub-id pub-id-type="pmid">37272513</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):491&#x02013;503.<pub-id pub-id-type="pmid">37272513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Xing</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name><etal/></person-group><article-title>Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial</article-title><source>JAMA</source><year>2024</year><volume>331</volume><issue>3</issue><fpage>201</fpage><lpage>211</lpage><?supplied-pmid 38227033?><pub-id pub-id-type="pmid">38227033</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, Xing W, Chen Q, Yang L, Mei J, et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024;331(3):201&#x02013;11.<pub-id pub-id-type="pmid">38227033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Dudnik</surname><given-names>E</given-names></name><name><surname>Moskovitz</surname><given-names>M</given-names></name><name><surname>Rottenberg</surname><given-names>Y</given-names></name><name><surname>Lobachov</surname><given-names>A</given-names></name><name><surname>Mandelboim</surname><given-names>R</given-names></name><name><surname>Shochat</surname><given-names>T</given-names></name><name><surname>Urban</surname><given-names>D</given-names></name><name><surname>Wollner</surname><given-names>M</given-names></name><name><surname>Nechushtan</surname><given-names>H</given-names></name><name><surname>Rotem</surname><given-names>O</given-names></name><etal/></person-group><article-title>Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) &#x02265;50%: real-world data</article-title><source>Oncoimmunology</source><year>2021</year><volume>10</volume><issue>1</issue><fpage>1865653</fpage><?supplied-pmid 33552685?><pub-id pub-id-type="pmid">33552685</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, et al. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) &#x02265;50%: real-world data. Oncoimmunology. 2021;10(1):1865653.<pub-id pub-id-type="pmid">33552685</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Takumida</surname><given-names>H</given-names></name><name><surname>Horinouchi</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Shinno</surname><given-names>Y</given-names></name><name><surname>Okuma</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Ohe</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression</article-title><source>Cancer Immunol Immunother</source><year>2022</year><volume>71</volume><issue>3</issue><fpage>737</fpage><lpage>746</lpage><?supplied-pmid 34389874?><pub-id pub-id-type="pmid">34389874</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Takumida H, Horinouchi H, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y. Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer Immunol Immunother. 2022;71(3):737&#x02013;46.<pub-id pub-id-type="pmid">34389874</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>C</given-names></name><name><surname>Bian</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><issue>1</issue><fpage>1932</fpage><?supplied-pmid 39994201?><pub-id pub-id-type="pmid">39994201</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yi C, Bian D, Wang J, Hu S, Sun L, Yan Y, Wang S, Shen Z, Yu H, Yang Y, et al. Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial. Nat Commun. 2025;16(1):1932.<pub-id pub-id-type="pmid">39994201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Aokage</surname><given-names>K</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Kumagai</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Yoh</surname><given-names>K</given-names></name><name><surname>Wakabayashi</surname><given-names>M</given-names></name><name><surname>Fukutani</surname><given-names>M</given-names></name><name><surname>Furuya</surname><given-names>H</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY)</article-title><source>Clin Cancer Res</source><year>2024</year><volume>30</volume><issue>24</issue><fpage>5584</fpage><lpage>5592</lpage><?supplied-pmid 39453771?><pub-id pub-id-type="pmid">39453771</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, et al. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clin Cancer Res. 2024;30(24):5584&#x02013;92.<pub-id pub-id-type="pmid">39453771</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Righi</surname><given-names>E</given-names></name><name><surname>Kamoun</surname><given-names>WS</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name><name><surname>Nezivar</surname><given-names>J</given-names></name><name><surname>Santosuosso</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Martin</surname><given-names>MR</given-names></name><name><surname>Vianello</surname><given-names>F</given-names></name><etal/></person-group><article-title>Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><issue>43</issue><fpage>17561</fpage><lpage>17566</lpage><?supplied-pmid 23045683?><pub-id pub-id-type="pmid">23045683</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561&#x02013;6.<pub-id pub-id-type="pmid">23045683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>TA</given-names></name><name><surname>Parkes</surname><given-names>EE</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Moyers</surname><given-names>JT</given-names></name><name><surname>Curran</surname><given-names>MA</given-names></name><name><surname>Tawbi</surname><given-names>HA</given-names></name></person-group><article-title>Development of Immunotherapy Combination Strategies in Cancer</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><issue>6</issue><fpage>1368</fpage><lpage>1397</lpage><?supplied-pmid 33811048?><pub-id pub-id-type="pmid">33811048</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021;11(6):1368&#x02013;97.<pub-id pub-id-type="pmid">33811048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial</article-title><source>Lancet Respir Med</source><year>2021</year><volume>9</volume><issue>3</issue><fpage>305</fpage><lpage>314</lpage><?supplied-pmid 33347829?><pub-id pub-id-type="pmid">33347829</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305&#x02013;14.<pub-id pub-id-type="pmid">33347829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Provencio</surname><given-names>M</given-names></name><name><surname>Nadal</surname><given-names>E</given-names></name><name><surname>Gonz&#x000e1;lez-Larriba</surname><given-names>JL</given-names></name><name><surname>Mart&#x000ed;nez-Mart&#x000ed;</surname><given-names>A</given-names></name><name><surname>Bernab&#x000e9;</surname><given-names>R</given-names></name><name><surname>Bosch-Barrera</surname><given-names>J</given-names></name><name><surname>Casal-Rubio</surname><given-names>J</given-names></name><name><surname>Calvo</surname><given-names>V</given-names></name><name><surname>Insa</surname><given-names>A</given-names></name><name><surname>Ponce</surname><given-names>S</given-names></name><etal/></person-group><article-title>Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>6</issue><fpage>504</fpage><lpage>513</lpage><?supplied-pmid 37379158?><pub-id pub-id-type="pmid">37379158</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Provencio M, Nadal E, Gonz&#x000e1;lez-Larriba JL, Mart&#x000ed;nez-Mart&#x000ed; A, Bernab&#x000e9; R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):504&#x02013;13.<pub-id pub-id-type="pmid">37379158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaft</surname><given-names>JE</given-names></name><name><surname>Oezkan</surname><given-names>F</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Bunn</surname><given-names>PA</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Kwiatkowski</surname><given-names>DJ</given-names></name><name><surname>Owen</surname><given-names>DH</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>10</issue><fpage>2155</fpage><lpage>2161</lpage><?supplied-pmid 36097216?><pub-id pub-id-type="pmid">36097216</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155&#x02013;61.<pub-id pub-id-type="pmid">36097216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Spicer</surname><given-names>JD</given-names></name><name><surname>Garassino</surname><given-names>MC</given-names></name><name><surname>Wakelee</surname><given-names>H</given-names></name><name><surname>Liberman</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Tsuboi</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Chen</surname><given-names>KN</given-names></name><name><surname>Dooms</surname><given-names>C</given-names></name><name><surname>Majem</surname><given-names>M</given-names></name><etal/></person-group><article-title>Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2024</year><volume>404</volume><issue>10459</issue><fpage>1240</fpage><lpage>1252</lpage><?supplied-pmid 39288781?><pub-id pub-id-type="pmid">39288781</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240&#x02013;52.<pub-id pub-id-type="pmid">39288781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Chailangkarn</surname><given-names>T</given-names></name><name><surname>Teeravechyan</surname><given-names>S</given-names></name><name><surname>Attasombat</surname><given-names>K</given-names></name><name><surname>Thaweerattanasinp</surname><given-names>T</given-names></name><name><surname>Sunchatawirul</surname><given-names>K</given-names></name><name><surname>Suwanwattana</surname><given-names>P</given-names></name><name><surname>Pongpirul</surname><given-names>K</given-names></name><name><surname>Jongkaewwattana</surname><given-names>A</given-names></name></person-group><article-title>Monkeypox virus productively infects human induced pluripotent stem cell-derived astrocytes and neural progenitor cells</article-title><source>J Infect</source><year>2022</year><volume>85</volume><issue>6</issue><fpage>702</fpage><lpage>769</lpage><?supplied-pmid 36272454?><pub-id pub-id-type="pmid">36272454</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chailangkarn T, Teeravechyan S, Attasombat K, Thaweerattanasinp T, Sunchatawirul K, Suwanwattana P, Pongpirul K, Jongkaewwattana A. Monkeypox virus productively infects human induced pluripotent stem cell-derived astrocytes and neural progenitor cells. J Infect. 2022;85(6):702&#x02013;69.<pub-id pub-id-type="pmid">36272454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial</article-title><source>J Thorac Oncol</source><year>2022</year><volume>17</volume><issue>4</issue><fpage>544</fpage><lpage>557</lpage><?supplied-pmid 34923163?><pub-id pub-id-type="pmid">34923163</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, Pan Y, Fang Y, Wang Q, Huang Y, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2022;17(4):544&#x02013;57.<pub-id pub-id-type="pmid">34923163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial</article-title><source>JAMA Oncol</source><year>2023</year><volume>9</volume><issue>10</issue><fpage>1348</fpage><lpage>1355</lpage><?supplied-pmid 37535377?><pub-id pub-id-type="pmid">37535377</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, Liu H, Gu Z, Huang L, Lu Q, et al. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. JAMA Oncol. 2023;9(10):1348&#x02013;55.<pub-id pub-id-type="pmid">37535377</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>D</given-names></name><name><surname>Depypere</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>F</given-names></name><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study</article-title><source>Int J Cancer</source><year>2022</year><volume>151</volume><issue>1</issue><fpage>128</fpage><lpage>137</lpage><?supplied-pmid 35188268?><pub-id pub-id-type="pmid">35188268</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, Li Z, Cui F, Du Z, Zeng Y, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 2022;151(1):128&#x02013;37.<pub-id pub-id-type="pmid">35188268</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>WT</given-names></name><name><surname>Xia</surname><given-names>RH</given-names></name><name><surname>Zhu</surname><given-names>DW</given-names></name><name><surname>Dou</surname><given-names>SJ</given-names></name><name><surname>Zhu</surname><given-names>GP</given-names></name><name><surname>Dong</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>LZ</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>TC</given-names></name><name><surname>Zhou</surname><given-names>ZH</given-names></name><etal/></person-group><article-title>A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>5378</fpage><?supplied-pmid 36104359?><pub-id pub-id-type="pmid">36104359</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ju WT, Xia RH, Zhu DW, Dou SJ, Zhu GP, Dong MJ, Wang LZ, Sun Q, Zhao TC, Zhou ZH, et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun. 2022;13(1):5378.<pub-id pub-id-type="pmid">36104359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Pang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><issue>7</issue><fpage>1258</fpage><lpage>1267.e1252</lpage><?supplied-pmid 38906157?><pub-id pub-id-type="pmid">38906157</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, Zhang Z, Wang Q, Yao J, Wang H, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42(7):1258-1267.e1252.<pub-id pub-id-type="pmid">38906157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>WL</given-names></name><name><surname>Chua</surname><given-names>KLM</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>VHF</given-names></name><name><surname>Tho</surname><given-names>LM</given-names></name><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Ho</surname><given-names>GF</given-names></name><name><surname>Reungwetwattana</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC</article-title><source>J Thorac Oncol</source><year>2020</year><volume>15</volume><issue>3</issue><fpage>324</fpage><lpage>343</lpage><?supplied-pmid 31733357?><pub-id pub-id-type="pmid">31733357</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, et al. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2020;15(3):324&#x02013;43.<pub-id pub-id-type="pmid">31733357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>AP</given-names></name><name><surname>Adashek</surname><given-names>JJ</given-names></name><name><surname>Reuss</surname><given-names>JE</given-names></name><name><surname>West</surname><given-names>HJ</given-names></name><name><surname>Mansfield</surname><given-names>AS</given-names></name></person-group><article-title>Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review</article-title><source>JAMA Oncol</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>135</fpage><lpage>142</lpage><?supplied-pmid 36394834?><pub-id pub-id-type="pmid">36394834</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Desai AP, Adashek JJ, Reuss JE, West HJ, Mansfield AS. Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review. JAMA Oncol. 2023;9(1):135&#x02013;42.<pub-id pub-id-type="pmid">36394834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><etal/></person-group><article-title>Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial</article-title><source>J Thorac Oncol</source><year>2023</year><volume>18</volume><issue>6</issue><fpage>780</fpage><lpage>791</lpage><?supplied-pmid 36870519?><pub-id pub-id-type="pmid">36870519</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Zhao J, Zhao L, Guo W, Wang S, Tao X, Li L, Mao Y, Tan F, Gao Y, Wu N, et al. Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial. J Thorac Oncol. 2023;18(6):780&#x02013;91.<pub-id pub-id-type="pmid">36870519</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><etal/></person-group><article-title>Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm</article-title><source>Phase II Trial J Clin Oncol</source><year>2020</year><volume>38</volume><issue>34</issue><fpage>4095</fpage><lpage>4106</lpage><?supplied-pmid 33052760?><pub-id pub-id-type="pmid">33052760</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lan C, Shen J, Wang Y, Li J, Liu Z, He M, Cao X, Ling J, Huang J, Zheng M, et al. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm. Phase II Trial J Clin Oncol. 2020;38(34):4095&#x02013;106.<pub-id pub-id-type="pmid">33052760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>T</given-names></name><etal/></person-group><article-title>Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label</article-title><source>Phase II Trial Clin Cancer Res</source><year>2021</year><volume>27</volume><issue>4</issue><fpage>1003</fpage><lpage>1011</lpage><?supplied-pmid 33087333?><pub-id pub-id-type="pmid">33087333</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label. Phase II Trial Clin Cancer Res. 2021;27(4):1003&#x02013;11.<pub-id pub-id-type="pmid">33087333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><etal/></person-group><article-title>Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial</article-title><source>Lancet Gastroenterol Hepatol</source><year>2022</year><volume>7</volume><issue>3</issue><fpage>245</fpage><lpage>253</lpage><?supplied-pmid 34998471?><pub-id pub-id-type="pmid">34998471</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):245&#x02013;53.<pub-id pub-id-type="pmid">34998471</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC</article-title><source>J Thorac Oncol</source><year>2024</year><volume>19</volume><issue>3</issue><fpage>465</fpage><lpage>475</lpage><?supplied-pmid 37879536?><pub-id pub-id-type="pmid">37879536</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C, Zhou J, Yu X, Hu Y, Zhang X, et al. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2024;19(3):465&#x02013;75.<pub-id pub-id-type="pmid">37879536</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>